Cahill C A, Matthews J D, Akil H
J Clin Endocrinol Metab. 1983 May;56(5):992-7. doi: 10.1210/jcem-56-5-992.
This is a report of the development, calibration, and validation of a series of techniques required to measure beta-endorphin (beta-END)-like immunoreactivity in human plasma, including sieve and affinity chromatography. The RIA, which uses the antibody Brenda, is very sensitive (IC50 = 5-15 fmol/tube at a final concentration of 1:40,000). The extraction process, which uses the Sep-Pak C18 cartridge (Waters Associates, Inc.), is simple and rapid and has a recovery rate of more than 90%. It extracts proopiomelanocortin, beta-lipotropin, and beta-END. Physiological validation was provided by the measurement of beta-END-like immunoreactivity in a pool of plasma of normal humans (2.25 fmol/ml plasma), two pregnant women at term (9.5 and 10.75 fmol/ml), and one patient with Nelson's disease (2 pmol/ml plasma).
这是一份关于测量人血浆中β-内啡肽(β-END)样免疫反应性所需的一系列技术的开发、校准和验证的报告,包括筛析和亲和色谱法。使用抗体Brenda的放射免疫分析(RIA)非常灵敏(在最终浓度为1:40,000时,IC50 = 5 - 15 fmol/管)。使用Sep-Pak C18柱(沃特斯联合公司)的提取过程简单快速,回收率超过90%。它能提取促阿片黑素皮质素、β-促脂素和β-END。通过测量正常人类血浆池(2.25 fmol/ml血浆)、两名足月孕妇(9.5和10.75 fmol/ml)以及一名尼尔森病患者(2 pmol/ml血浆)中的β-END样免疫反应性进行了生理验证。